Tissue transglutaminase (tTG) is an enzyme found throughout your body that cross-links proteins together, stabilizing tissues and helping with wound repair. Most people encounter this term for the first time on a lab order, because a blood test measuring antibodies against this enzyme is the primary screening tool for celiac disease. Understanding what tTG actually does, and why your immune system might target it, helps make sense of both the test and the condition.
What tTG Does in Healthy Tissue
Tissue transglutaminase, also called TG2 or transglutaminase 2, is one of the most versatile enzymes in the human body. It’s present in nearly every tissue type, which is unusual for an enzyme in this family. Its best-known job is protein cross-linking: it creates strong, covalent bonds between proteins, essentially spot-welding them together into stable structures. These cross-linked proteins become highly resistant to mechanical stress and breakdown.
This cross-linking activity plays a direct role in how your body maintains and repairs the extracellular matrix, the scaffolding that holds cells in place. tTG strengthens this scaffolding in several ways. It increases the rigidity of the surfaces cells attach to, it builds ordered protein networks that help cells grip and communicate with their surroundings, and it exposes hidden binding sites on matrix proteins that cells can latch onto. The resulting structures are so stable that researchers have described tTG as functioning like a “reverse proteinase,” making proteins harder to break down rather than easier.
Beyond structural work, tTG is involved in cell adhesion, migration, growth, survival, and programmed cell death (apoptosis). It has a complicated relationship with apoptosis specifically: in some contexts it blocks cell death by cross-linking and inactivating the enzymes that execute apoptosis, while in other situations it can promote it. This dual role makes tTG a factor in wound healing, inflammation, tissue scarring (fibrosis), and even tumor growth.
How tTG Triggers Celiac Disease
In celiac disease, tTG becomes the central player in a case of mistaken identity. When someone with celiac disease eats gluten, partially digested gluten fragments called gliadin peptides enter the lining of the small intestine. There, tTG does what it normally does: it chemically modifies these peptides. Specifically, it converts certain glutamine amino acids in the gliadin fragments into glutamic acid, a process called deamidation. This swap introduces negative charges at precise positions on the peptide.
Those negatively charged positions happen to fit perfectly into the binding grooves of specific immune molecules called HLA-DQ2 or HLA-DQ8, which are present in people genetically predisposed to celiac disease. The modified gliadin peptides bind to these molecules with much higher affinity than unmodified ones, which ramps up the immune response dramatically. The immune system then generates antibodies not only against the modified gliadin but also against tTG itself. That’s why measuring anti-tTG antibodies in the blood works as a celiac disease test: elevated levels signal that this immune cascade is active.
The tTG-IgA Blood Test
The tTG-IgA test measures antibodies of the IgA class directed against tissue transglutaminase. It is the preferred first-line blood test for celiac disease screening. According to the National Institute of Diabetes and Digestive and Kidney Diseases, the test has a sensitivity of 78% to 100% and a specificity of 90% to 100%, making it both reliable at catching true cases and good at ruling out false alarms.
Reference ranges from Mayo Clinic Labs break down as follows:
- Below 4.0 U/mL: negative
- 4.0 to 10.0 U/mL: weak positive
- Above 10.0 U/mL: positive
A strong positive result, particularly levels well above 10 U/mL, is highly suggestive of celiac disease. In many clinical guidelines, very high tTG-IgA levels (often defined as ten times the upper limit of normal) combined with a positive confirmatory antibody test can support a celiac diagnosis even without a biopsy, especially in children.
When Standard Testing Doesn’t Work
About 2% to 3% of people with celiac disease also have selective IgA deficiency, a condition where the body produces very little IgA antibody overall. In these cases, the tTG-IgA test will come back falsely low regardless of whether celiac disease is present. When IgA deficiency is known or suspected, labs can run IgG-based alternatives: the tTG-IgG test, the deamidated gliadin peptide IgG test, or the endomysial antibody IgG test. These detect a different antibody class and fill the diagnostic gap.
Conditions That Can Cause False Positives
A positive tTG-IgA result doesn’t always mean celiac disease. Elevated levels have been documented in people with inflammatory bowel disease, food allergies, irritable bowel syndrome, iron-deficiency anemia, giardiasis and other intestinal infections, and various autoimmune disorders. These conditions can cause enough intestinal inflammation or immune activation to produce low-level anti-tTG antibodies. This is one reason why a positive blood test is typically followed by additional testing or a small intestinal biopsy to confirm celiac disease.
tTG and Dermatitis Herpetiformis
Dermatitis herpetiformis is a blistering, intensely itchy skin rash that affects some people with gluten sensitivity. For years, researchers were puzzled about why only a subset of celiac patients developed skin symptoms. The answer turned out to involve a close relative of tTG: epidermal transglutaminase, also called TG3.
People with dermatitis herpetiformis produce antibodies against both tTG and epidermal transglutaminase, but their antibodies bind epidermal transglutaminase with notably higher affinity. More importantly, the IgA deposits found in the skin of dermatitis herpetiformis patients, which are the hallmark of the disease, contain epidermal transglutaminase but not tTG. So while tTG drives the intestinal component of celiac disease, it is epidermal transglutaminase that drives the skin manifestation. Both conditions respond to a gluten-free diet because the underlying trigger is the same.
How tTG Levels Change on a Gluten-Free Diet
After starting a strict gluten-free diet, tTG antibody levels gradually fall as the immune reaction quiets down. A study in pediatric celiac patients found that roughly half of patients see their tTG levels return to normal within 6 to 12 months. The timeline depends heavily on how high the levels were at diagnosis: patients with very elevated initial titers take longer to normalize, sometimes well beyond a year. Clinicians often recheck tTG-IgA levels periodically after diagnosis to confirm that the diet is working and the immune response is subsiding.
Persistently elevated tTG levels despite a gluten-free diet usually point to ongoing gluten exposure, whether intentional or from hidden sources in processed foods, shared cooking surfaces, or cross-contact during food preparation. In rare cases, persistent elevation can signal refractory celiac disease, a form that doesn’t respond to dietary changes alone.